Literature DB >> 33323408

Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer.

Amy J Wisdom1, David G Kirsch2,3.   

Abstract

DNA polymerase mutations can cause hypermutant cancers, but the mechanisms of tumorigenesis and the impact of various DNA polymerase mutations on treatment response is poorly understood. In this issue of Cancer Research, Galati and colleagues investigate the effects of cancer-associated DNA polymerase ϵ (Pole) mutations on tumorigenesis and response to immune checkpoint blockade. They describe novel genetically engineered mouse models harboring cancer-associated Pole mutations and examine the effects of these mutations on tumorigenesis, the tumor mutational landscape, and the tumor immune microenvironment. Integrating this information with an emerging understanding of how different tumor mutations influence the response to immunotherapy may aid in prediction, diagnosis, and treatment of Pole-mutant tumors.See related article by Galati et al., p. 5606. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33323408      PMCID: PMC7931142          DOI: 10.1158/0008-5472.CAN-20-3241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention.

Authors:  Cristian Tomasetti; Lu Li; Bert Vogelstein
Journal:  Science       Date:  2017-03-24       Impact factor: 47.728

2.  Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade.

Authors:  Melissa A Galati; Karl P Hodel; Zachary F Pursell; Uri Tabori; Miki S Gams; Sumedha Sudhaman; Taylor Bridge; Walter J Zahurancik; Nathan A Ungerleider; Vivian S Park; Ayse B Ercan; Lazar Joksimovic; Iram Siddiqui; Robert Siddaway; Melissa Edwards; Richard de Borja; Dana Elshaer; Jiil Chung; Victoria J Forster; Nuno M Nunes; Melyssa Aronson; Xia Wang; Jagadeesh Ramdas; Andrea Seeley; Tomasz Sarosiek; Gavin P Dunn; Jonathan N Byrd; Oz Mordechai; Carol Durno; Alberto Martin; Adam Shlien; Eric Bouffet; Zucai Suo; James G Jackson; Cynthia E Hawkins; Cynthia J Guidos
Journal:  Cancer Res       Date:  2020-09-16       Impact factor: 12.701

3.  A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.

Authors:  Hao-Dong Li; Changzheng Lu; He Zhang; Qing Hu; Junqiu Zhang; Ileana C Cuevas; Subhransu S Sahoo; Mitzi Aguilar; Elizabeth G Maurais; Shanrong Zhang; Xiaojing Wang; Esra A Akbay; Guo-Min Li; Bo Li; Prasad Koduru; Peter Ly; Yang-Xin Fu; Diego H Castrillon
Journal:  JCI Insight       Date:  2020-07-23

4.  Comprehensive Analysis of Hypermutation in Human Cancer.

Authors:  Brittany B Campbell; Nicholas Light; David Fabrizio; Matthew Zatzman; Fabio Fuligni; Richard de Borja; Scott Davidson; Melissa Edwards; Julia A Elvin; Karl P Hodel; Walter J Zahurancik; Zucai Suo; Tatiana Lipman; Katharina Wimmer; Christian P Kratz; Daniel C Bowers; Theodore W Laetsch; Gavin P Dunn; Tanner M Johanns; Matthew R Grimmer; Ivan V Smirnov; Valérie Larouche; David Samuel; Annika Bronsema; Michael Osborn; Duncan Stearns; Pichai Raman; Kristina A Cole; Phillip B Storm; Michal Yalon; Enrico Opocher; Gary Mason; Gregory A Thomas; Magnus Sabel; Ben George; David S Ziegler; Scott Lindhorst; Vanan Magimairajan Issai; Shlomi Constantini; Helen Toledano; Ronit Elhasid; Roula Farah; Rina Dvir; Peter Dirks; Annie Huang; Melissa A Galati; Jiil Chung; Vijay Ramaswamy; Meredith S Irwin; Melyssa Aronson; Carol Durno; Michael D Taylor; Gideon Rechavi; John M Maris; Eric Bouffet; Cynthia Hawkins; Joseph F Costello; M Stephen Meyn; Zachary F Pursell; David Malkin; Uri Tabori; Adam Shlien
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

5.  DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice.

Authors:  Tina M Albertson; Masanori Ogawa; James M Bugni; Laura E Hays; Yang Chen; Yanping Wang; Piper M Treuting; John A Heddle; Robert E Goldsby; Bradley D Preston
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-24       Impact factor: 11.205

6.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Authors:  Razvan Cristescu; Robin Mogg; Mark Ayers; Andrew Albright; Erin Murphy; Jennifer Yearley; Xinwei Sher; Xiao Qiao Liu; Hongchao Lu; Michael Nebozhyn; Chunsheng Zhang; Jared K Lunceford; Andrew Joe; Jonathan Cheng; Andrea L Webber; Nageatte Ibrahim; Elizabeth R Plimack; Patrick A Ott; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan; Joanne E Tomassini; Andrey Loboda; David Kaufman
Journal:  Science       Date:  2018-10-12       Impact factor: 47.728

Review 7.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

8.  PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.

Authors:  Tim Wartewig; Zsuzsanna Kurgyis; Selina Keppler; Konstanze Pechloff; Erik Hameister; Rupert Öllinger; Roman Maresch; Thorsten Buch; Katja Steiger; Christof Winter; Roland Rad; Jürgen Ruland
Journal:  Nature       Date:  2017-11-15       Impact factor: 49.962

9.  Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.

Authors:  Marka R Crittenden; Lauren Zebertavage; Gwen Kramer; Shelly Bambina; David Friedman; Victoria Troesch; Tiffany Blair; Jason R Baird; Alejandro Alice; Michael J Gough
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

10.  Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.

Authors:  Amy J Wisdom; Yvonne M Mowery; Cierra S Hong; Jonathon E Himes; Barzin Y Nabet; Xiaodi Qin; Dadong Zhang; Lan Chen; Hélène Fradin; Rutulkumar Patel; Alex M Bassil; Eric S Muise; Daniel A King; Eric S Xu; David J Carpenter; Collin L Kent; Kimberly S Smythe; Nerissa T Williams; Lixia Luo; Yan Ma; Ash A Alizadeh; Kouros Owzar; Maximilian Diehn; Todd Bradley; David G Kirsch
Journal:  Nat Commun       Date:  2020-12-17       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.